Assess whether to resubmit, meet, or pause the program (813dbf)

SITUATION 505(b)(2) literature-to-product bridge table arrived with an AdCom briefing document that overstates subgroup findings for regulatory-affairs lead. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on to resubmit, meet, or in a labeling team facing a boxed-warning debate.

DECISION Regulatory-affairs lead in a labeling team facing a boxed-warning debate must choose To resubmit, meet, / Pause the program using 505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; 505(b)(2) literature-to-product bridge table already has the discriminator after an AdCom briefing document that overstates subgroup findings. 2. Keep Pause the program in force until 505(b)(2) literature-to-product bridge table is completed after an AdCom briefing document that overstates subgroup findings for regulatory-affairs lead. 3. Treat 505(b)(2) literature-to-product bridge table as To resubmit, meet, because both readings appear after an AdCom briefing document that overstates subgroup findings. 4. Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the decision to resubmit, meet, or turns on in 505(b)(2) literature-to-product bridge table.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 2. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim regulatory-affairs lead would keep. 3. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to resubmit, meet, or for regulatory-affairs lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after an AdCom briefing document that overstates subgroup findings, then the two facts that force it, then the Monday action for regulatory-affairs lead in a labeling team facing a boxed-warning debate.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for regulatory-affairs lead - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - What changes to resubmit, meet, or if an AdCom briefing document that overstates subgroup findings is later withdrawn - Named option among To resubmit, meet,, Pause the program and the fact that kills the others